Natera announced the commercial launch of Zenith Genomics, a whole genome sequencing assay for rare disease diagnosis. The company said Zenith uses long-read sequencing confirmation to detect features such as tandem repeat expansions. Natera said the assay’s underlying technology was developed by MyOme under an exclusive partnership, with Natera distributing Zenith to healthcare providers across the U.S. using its EMR integration footprint and clinical support system. At the 2026 ACMG Annual Clinical Genetics Meeting, Natera is presenting data on the Zenith platform and performance, with additional information available here.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.